App-Quantinova.ai

Differences in cerebral blood flow in early stage breast cancer survivors in comparison to healthy women.

Hibba tul Rehman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Trends and correlates of secondhand smoke exposure among non-smoking cancer survivors in the United States: 1999-2012.

Oladimeji Akinboro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Optimal weight control strategies in cancer patients: A systematic review.

Nathalie LeVasseur - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin.

Hironobu Hashimoto - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Olanzapine

Duration of anticoagulant therapy and VTE recurrence in patients with cancer.

Alok A. Khorana - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

rivaroxaban

Follow the TRAIL: Understanding the etiology of persistent fatigue following radiation therapy.

Leorey N Saligan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Comparison of treatment-related fatigue and tolerability between PD-1 immune checkpoint inhibitors and chemotherapy: A meta-analysis.

Tomohiro F. Nishijima - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Patient reported outcomes using Internet-based tablets to inform hospice care for minority and nonminority patients with cancer.

Timothy McCurry - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors.

Zefei Jiang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Alkaline phosphatase

Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in women treated for either breast or female genital tract cancer: A German experience using the Paxman system.

Christian M. Kurbacher - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

taxane

Phase Ib trial of superoxide (SO) dismutase (SOD) mimetic GC4419 to reduce chemoradiotherapy (CRT)-induced oral mucositis (OM) in patients (pts) with oral cavity or oropharyngeal carcinoma (OCC).

Carryn M. Anderson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

GC4419

Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer.

Lee Steven Schwartzberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Dexamethasone

Rolapitant for control of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer.

Bernardo Leon Rapoport - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Dexamethasone

Relationship between symptom burden and hospital length of stay (LOS) in patients with incurable cancer.

Ryan David Nipp - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of YOCAS yoga and influence of sleep and fatigue on quality of life (QOL) in breast cancer survivors.

Anita Roselyn Peoples - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Early integrated palliative care to improve family caregivers (FC) outcomes for patients with gastrointestinal and lung cancer.

Areej El-Jawahri - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Early palliative care for improving quality of life and survival time in adults with advanced cancer: Meta-analytical findings from a Cochrane Review.

Markus W. Haun - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Efficacy of selective screening in identifying patients with hepatitis B before cancer therapy.

Jessica Hwang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Romiplostim management of chemotherapy-induced thrombocytopenia.

Gerald A. Soff - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Romiplostim

Analysis of nationwide trends and outcomes of percutaneous endoscopic gastrostomy (PEG) tube placement in hospitalized cancer patients over a 13 year period.

Padma L. Draksharam - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts